ChromaDex Corporation

AI Score

0

Unlock

6.00
0.08 (1.35%)
Jan 23, 2025, 3:10 PM - Market open
1.35%
Bid 5.99
Market Cap 458.30M
Revenue (ttm) 101.55M
Net Income (ttm) 1.49M
EPS (ttm) 0.02
PE Ratio (ttm) 300
Forward PE 60.42
Analyst Strong Buy
Ask 6
Volume 189,349
Avg. Volume (20D) 1,373,193
Open 5.90
Previous Close 5.92
Day's Range 5.78 - 6.02
52-Week Range 1.45 - 7.97
Beta 1.88

About CDXC

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-b...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 25, 2008
Employees 106
Stock Exchange NASDAQ
Ticker Symbol CDXC

Analyst Forecast

According to 2 analyst ratings, the average rating for CDXC stock is "Strong Buy." The 12-month stock price forecast is $8, which is an increase of 33.33% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

ChromaDex Corporation is scheduled to release its earnings on Mar 5, 2025, during market hours.
Analysts project revenue of $26.52M, reflecting a 25.12% YoY growth and earnings per share of 0.02.
2 months ago
+14.4%
ChromaDex shares are trading higher after Roth MKM... Unlock content with Pro Subscription
2 months ago
+67.91%
ChromaDex shares are trading higher after the company reported a year-over-year increase in Q3 EPS results and raised its FY24 revenue guidance.